Clinical & Translational Radiation Oncology

👉 94 patients with isolated local relapse of prostate cancer after definitive irradiation. 👉 Salvage I-125 low-dose-rate brachytherapy was performed in a Comprehensive Cancer Center. 👉 Treatment of whole gland (70%) +- with an MRI-based GTV boost (20%) or focal (10%).

Compliance to MDT recs in OMD pts: 👉83.7% of MDT recommendations correctly implemented 👉Reasons for major deviations: physician decision, patient comorbidity or patient decision. 👉Major deviations associated with more than one distant met and worse OS doi.org/10.1016/j.ctro…

A day in the life of an editor in chief... @ctro_journal #radonc

👉Nomogram developed by authors predicting outcomes. #radonc

🎆 Now in @ctRO_journal Impact of Dose, fractionation and motion management on SBRT outcome in adrenal gland tumors. #radonc

Also don't miss the accompanying editorial by @cristian_udo @SahgalArjun @HaghighiNeda @drhsoli ctro.science/article/S2405-… #radonc

Hot off the press in ctRO by Rogers et al. 🔷 Preoperative Radiosurgery is highly feasible when scheduled the day before neurosurgery. 🔷 The surgical cavity local control rate was equivalent to that reported with postoperative fractionated SRS ctro.science/article/S2405-… #radonc

Should preoperative SRS be considered for brain metastases undergoing resection? Great to work with @HaghighiNeda @SahgalArjun @drhsoli on our @ctRO_journal editorial of the PREOP-1 trial. More prospective evidence for this novel paradigm! @Sunnybrook @UofTDRO @PeterMacRadOnc @PeterMacCC @ESTRO_RT @RadiotherapyOn1 #btsm

🔹LDR Brachytherapy for recurrent prostate cancer after definitive radiotherapy ctro.science/article/S2405-… #radonc

🦴 Study on Osteolytic Metastases (SM) Remineralization 🔬 Conclusion: Radiation therapy significantly increases BMD in lytic SM (except renal tumors). No additional benefit of SBRT over cEBRT. Important for surgical decisions in unstable patients. ctro.science/article/S2405-…

We are hiring!! We are looking for two associate editors for @ctro_journal! Apply now if you want to be part of a rapidly growing radiotherapy journal by @ESTRO_RT! ctro.science/content/callfo… #radonc

And now... updated results of 41 patients CURATIVELY treated with 6m of Dostarlimab (PD-1) WITHOUT ☢️or🔪 ✅100% cCR rate ✅0 Local or distance relapses ✅Sustained cCR for > 12 m seen in 20 patients with mFU of 29 m THIS. IS. AWESOME #ASCO24

LAURA Trial receives a well deserved huge applause by the audience. Huge benefit in PFS (39 vs 5.6 mo, HR < 0.2. OS still immature and 81% crossover. STAGE III EGFR+ NSCLC INCURABLE? BRAIN RMN BUT NO PET-CT required at baseline. #ASCO24 @LeciaSequist

Your turn now to submit 👍 ctro.science

...another fascinating study... ctro.science/article/S2405-…

🌟 Check out these examples showcasing the scope of @ctro_journal! 📝🔬 #radonc